Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
memo - Magazine of European Medical Oncology
Published in: memo - Magazine of European Medical Oncology 4/2023

13-11-2023 | Pancreatic Cancer | short review

Essential news from ASCO 2023 in primary resectable and advanced or metastatic pancreatic cancer

Authors: Patrick Reimann, M.D., Thomas Winder, M.D. PhD

Published in: memo - Magazine of European Medical Oncology | Issue 4/2023

Login to get access

Summary

In this short review, we aim to summarize the essential news and highlights in pancreatic cancer that were presented at ASCO 2023. We focus in particular on primary resectable as well as advanced or metastatic disease. Therefore, the first results of the NORPACT-1 trial and the updated data from the NAPOLI-3 study are summarized. We discuss these studies and their potential influence on daily clinical practice with regard to current standard of care.
Literature
1.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed
2.
Wainberg ZA, Melisi D, Macarulla T, Pazo-Cid R, Chandana SR, Fouchardiere CDL, et al. NAPOLI-3: A randomized, open-label phase 3 study of liposomal irinotecan + 5‑fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). J Clin Oncol. 2023;41(4_suppl):LBA661.CrossRef
3.
Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics. CA Cancer J Clin. 2023;73(1):17–48.CrossRefPubMed
4.
Haeno H, Gonen M, Davis MB, Herman JM, Iacobuzio-Donahue CA, Michor F. Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell. 2012;148(1–2):362–75.CrossRefPubMedPubMedCentral
5.
Yamaguchi J, Yokoyama Y, Fujii T, Yamada S, Takami H, Kawashima H, et al. Results of a phase II study on the use of neoadjuvant chemotherapy (FOLFIRINOX or GEM/nab-PTX) for borderline-resectable pancreatic cancer (NUPAT-01). Ann Surg. 2022;275(6):1043–9.CrossRefPubMed
6.
Janssen QP, Buettner S, Suker M, Beumer BR, Addeo P, Bachellier P, et al. Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis. J Natl Cancer Inst. 2019;111(8):782–94.CrossRefPubMedPubMedCentral
7.
Labori KJ, Bratlie SO, Biörserud C, Björnsson B, Bringeland E, Elander N, et al. Short-course neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer: A multicenter randomized phase-II trial (NORPACT-1). J Clin Oncol. 2023;41(17_suppl):LBA4005.CrossRef
8.
Tempero MA, Malafa MP, Al-Hawary M, Behrman SW, Benson AB, Cardin DB, et al. Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(4):439–57.CrossRefPubMed
9.
Wainberg ZA, Bekaii-Saab TS, Hubner R, Macarulla T, Paulson AS, Cutsem EV, et al. NAPOLI-3: An open-label, randomized, phase III study of first-line liposomal irinotecan + 5‑fluorouracil/leucovorin + oxaliplatin versus nab-paclitaxel + gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma. J Clin Oncol. 2020;38(15_suppl):TPS4661.CrossRef
10.
Al-Batran SE, Hofheinz RD, Pauligk C, Kopp HG, Haag GM, Luley KB, et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol. 2016;17(12):1697–708.CrossRefPubMed
11.
de Geus SW, Evans DB, Bliss LA, Eskander MF, Smith JK, Wolff RA, et al. Neoadjuvant therapy versus upfront surgical strategies in resectable pancreatic cancer: A Markov decision analysis. Eur J Surg Oncol. 2016;42(10):1552–60.CrossRefPubMed
12.
Gruenberger T, Bridgewater J, Chau I, García AP, Rivoire M, Mudan S, et al. Bevacizumab plus mFOLFOX‑6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. Ann Oncol. 2015;26(4):702–8.CrossRefPubMed
13.
Ruhstaller T, Thuss-Patience P, Hayoz S, Schacher S, Knorrenschild JR, Schnider A, et al. Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08). Ann Oncol. 2018;29(6):1386–93.CrossRefPubMed
14.
Kolbeinsson HM, Chandana S, Wright GP, Chung M. Pancreatic cancer: a review of current treatment and novel therapies. J Invest Surg. 2023;36(1):2129884.CrossRefPubMed
15.
Sohal DPS, Duong M, Ahmad SA, Gandhi NS, Beg MS, Wang-Gillam A, et al. Efficacy of perioperative chemotherapy for resectable pancreatic adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol. 2021;7(3):421–7.CrossRefPubMed
16.
Hatashima A, Arango MJ, Reardon J, Freeman T, Williams T, McLaughlin EM, et al. First-line gemcitabine plus nab-paclitaxel versus FOLFIRINOX for metastatic pancreatic cancer in a real-world population. Future Oncol. 2022;18(20):2521–32.CrossRefPubMedPubMedCentral
17.
Riedl JM, Posch F, Horvath L, Gantschnigg A, Renneberg F, Schwarzenbacher E, et al. Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: a propensity score analysis. Eur J Cancer. 2021;151:3–13.CrossRefPubMed
18.
Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–25.CrossRefPubMed
19.
Cavanna L, Stroppa EM, Citterio C, Mordenti P, Di Nunzio C, Peveri S, et al. Modified FOLFIRINOX for unresectable locally advanced/metastatic pancreatic cancer. A real-world comparison of an attenuated with a full dose in a single center experience. Onco Targets Ther. 2019;12:3077–85.CrossRefPubMedPubMedCentral
Metadata
Title
Essential news from ASCO 2023 in primary resectable and advanced or metastatic pancreatic cancer
Authors
Patrick Reimann, M.D.
Thomas Winder, M.D. PhD
Publication date
13-11-2023
Publisher
Springer Vienna
Published in
memo - Magazine of European Medical Oncology / Issue 4/2023
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-023-00931-z

Other articles of this Issue 4/2023

memo - Magazine of European Medical Oncology 4/2023 Go to the issue

short review

Second-line treatment of HER2-positive advanced gastroesophageal adenocarcinoma

short review

Management of malignant hypercalcemia in cancer patients—a short review

comment

Comment to Smith MR, Hussain M, Saad F et al. (2022, N Engl J Med) Darolutamide and survival in metastatic, hormone-sensitive prostate cancer

case report

Fifth-line HER2-directed therapy for metastatic adenocarcinoma of the gastroesophageal junction

short review

Imaging and therapy targeting PSMA receptors for enhanced vision and precise treatment

short review

Erythropoiesis-stimulating agents—benefits and harms in the treatment of anemia in cancer patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits